Subject(s)
Humans , HIV Infections/drug therapy , HIV Protease Inhibitors/administration & dosage , Ritonavir/administration & dosage , HIV-Associated Lipodystrophy Syndrome/chemically induced , Darunavir/administration & dosage , Triglycerides/blood , Prospective Studies , HIV Protease Inhibitors/adverse effects , Ritonavir/adverse effects , HIV-Associated Lipodystrophy Syndrome/blood , Drug Substitution , Darunavir/adverse effects , Cholesterol, LDL/bloodSubject(s)
Humans , Male , Antihypertensive Agents/administration & dosage , Benzimidazoles/administration & dosage , Benzoates/administration & dosage , HIV Infections/complications , Hypertension/drug therapy , HIV Infections/blood , Hypertension/blood , Hypertension/complications , Prospective Studies , Treatment OutcomeABSTRACT
In this case, a new possible strategy for treatment of hepatitis C virus (HCV) relapsing patients is described. The target of anti-HCV therapy is sustained viral response, but strategies for improving sustained viral response in relapsing patients would be useful, and ribavirin is crucial for obtaining viral response. Six weeks of induction therapy with ribavirin were used to improve efficacy of standard combined antiviral therapy in a patient relapsing to standard therapy. In the present case, the patient had undergone a retreatment with the same regimen with the exception of the six-week induction period with ribavirin. Use of induction therapy with ribavirin in this case has allowed for a sustained viral response without prolonging the interferon exposure time in retreatment.